- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07940101
Clinical and Electrophysiological Heterogeneity in Adult Charcot-Marie-Tooth Disease
Clinical and Electrophysiological Heterogeneity in Adult Charcot-Marie-Tooth Disease: An Observational Study of the Relationships Between CMTES-v2, Nerve Conduction Parameters, and Functional Capacity
CMT-PROFILE is a single-center, cross-sectional observational study involving adults with Charcot-Marie-Tooth disease (CMT). The study will investigate the association between clinical disease severity, measured using the CMT Examination Score version 2 (CMTES-v2), and motor electrophysiological parameters, including compound muscle action potential (CMAP) amplitudes and motor nerve conduction velocities. Secondary objectives include characterizing clinical-electrophysiological concordance, comparing functional capacity, muscle strength and mobility across concordance groups, and exploring demographic, clinical, biological and genetic factors associated with variability in disease expression. Approximately 250 patients are planned for inclusion. All assessments will be performed at a single reference time point (M0), with no longitudinal follow-up.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Abderhmane Slioui
- Telefonnummer: +33 0492038953
- E-Mail: slioui.a@chu-nice.fr
Studieren Sie die Kontaktsicherung
- Name: Angela Puma
- Telefonnummer: +33 0492035435
- E-Mail: puma.ar@chu-nice.fr
Studienorte
-
-
Alpes Maritimes
-
Nice, Alpes Maritimes, Frankreich, 06000
- CHU de Nice
-
Kontakt:
- Abderhmane Slioui
- Telefonnummer: +33 0492038953
- E-Mail: slioui.a@chu-nice.fr
-
Kontakt:
- Angela de Nice
- Telefonnummer: +33 0492035435
- E-Mail: puma.ar@chu-nice.fr
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Adults with Charcot-Marie-Tooth disease evaluated at the Peripheral Neuromuscular Rare Disease Reference Center of Nice University Hospital. The study aims to characterize the relationships between clinical disease severity, assessed using the CMTES-v2, motor electrophysiological parameters, and functional capacity. Participants will undergo a single reference assessment (M0), with no subsequent follow-up. The planned sample size is approximately 250 participants, subject to confirmation against the approved protocol.
Beschreibung
Inclusion Criteria:
- Adults aged 18 years or older.
- Diagnosis of peripheral sensory polyneuropathy.
- Classification as length-dependent (LDN) or non-length-dependent (NLDN) based on clinical and electrophysiological findings.
- Available nerve conduction study including sural and radial sensory nerve amplitudes allowing calculation of the SRAR.
- Evaluated at the Peripheral Neuromuscular Rare Disease Reference Center, Nice University Hospital, between January 2013 and July 2026.
Exclusion Criteria:
- Missing or incomplete clinical or electrophysiological data preventing SRAR calculation.
- Unclassifiable neuropathy phenotype.
- Technical factors affecting the reliability of nerve conduction studies.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: CROSS_SECTIONAL
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Adults with Charcot-Marie-Tooth Disease
|
This observational, cross-sectional study evaluates clinical severity, electrophysiological parameters, and functional capacity in adults with Charcot-Marie-Tooth disease (CMT). Data collected at a single reference time point (M0) include the CMT Examination Score version 2 (CMTES-v2), nerve conduction study parameters, including compound muscle action potential (CMAP) amplitudes and motor nerve conduction velocities, and available functional and clinical measures. Additional variables may include muscle strength, mobility, pain, patient-perceived disease severity, occupational impact, and demographic, clinical, and genetic characteristics, as specified in the study protocol. No study-specific treatment or intervention is administered. There is no longitudinal follow-up |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Association Between CMTES-v2 and Motor Electrophysiological Parameters
Zeitfenster: At day 0 (single assessment; no follow-up).
|
To assess the association between the CMTES-v2 total score and prespecified motor electrophysiological parameters, including distal CMAP amplitudes and motor nerve conduction velocities, using correlation analyses as specified in the statistical analysis plan. |
At day 0 (single assessment; no follow-up).
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Clinical-Electrophysiological Concordance and Discordance Classification
Zeitfenster: At Day 0 (single assessment; no follow-up).
|
disease severity and electrophysiological impairment, using standardized residuals derived from the difference between observed CMTES-v2 scores and scores predicted from motor electrophysiological parameters, divided by the residual standard deviation. Patients will be classified into three mutually exclusive categories: concordant (standardized residual between -1.96 and +1.96), greater clinical severity than predicted (standardized residual above +1.96), or lower clinical severity than predicted (standardized residual below -1.96). Results will be expressed as the number and percentage of patients in each category. |
At Day 0 (single assessment; no follow-up).
|
|
Age at Assessment Across Clinical-Electrophysiological Concordance Groups
Zeitfenster: At Day 0 (single assessment; no follow-up)
|
To investigate whether age at clinical assessment differs according to the degree of clinical-electrophysiological concordance, age will be recorded in years and compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Age at Symptom Onset Across Clinical-Electrophysiological Concordance Groups
Zeitfenster: At Day 0 (single assessment; no follow-up)
|
To investigate whether age at clinical assessment differs according to the degree of clinical-electrophysiological concordance, age will be recorded in years and compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Disease Duration Across Clinical-Electrophysiological Concordance Groups
Zeitfenster: At Day 0 (single assessment; no follow-up)
|
To evaluate the relationship between disease duration and clinical-electrophysiological concordance, disease duration will be calculated as the interval, expressed in years, between the reported onset of symptoms and the reference clinical assessment. Disease duration will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Genetic Subtype Distribution Across Clinical-Electrophysiological Concordance Groups
Zeitfenster: At Day 0 (single assessment; no follow-up)
|
To investigate whether the distribution of genetically confirmed Charcot-Marie-Tooth disease subtypes differs according to clinical-electrophysiological concordance, genetic subtypes documented in the medical records will be categorized and compared across the three predefined concordance groups. Results will be reported as the number and percentage of patients within each genetic subtype among those with available genetic data. |
At Day 0 (single assessment; no follow-up)
|
|
Functional Performance Across Clinical-Electrophysiological Concordance Groups (CMT-FOM)
Zeitfenster: At Day 0 (single assessment; no follow-up).
|
To evaluate whether functional performance differs according to clinical-electrophysiological concordance, functional capacity will be quantified using the total score of the Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM). Scores will be compared across the three predefined concordance groups among patients with available assessments. |
At Day 0 (single assessment; no follow-up).
|
|
Muscle Strength Across Clinical-Electrophysiological Concordance Groups (MRC Scale)
Zeitfenster: At Day 0 (single assessment; no follow-up)
|
To assess differences in muscle strength according to clinical-electrophysiological concordance, muscle strength will be evaluated using the Medical Research Council (MRC) grading scale, ranging from 0 (no visible or palpable muscle contraction) to 5 (normal muscle strength). Recorded muscle strength grades will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Right Handgrip Strength Across Clinical-Electrophysiological Concordance Groups
Zeitfenster: At Day 0 (single assessment; no follow-up)
|
To assess differences in right handgrip strength according to clinical-electrophysiological concordance, right handgrip strength will be measured by dynamometry, with the highest value obtained from three trials retained for analysis. Measurements will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Left Handgrip Strength Across Clinical-Electrophysiological Concordance Groups
Zeitfenster: At Day 0 (single assessment; no follow-up).
|
To assess differences in left handgrip strength according to clinical-electrophysiological concordance, left handgrip strength will be measured by dynamometry, with the highest value obtained from three trials retained for analysis. Measurements will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up).
|
|
Functional Mobility Across Clinical-Electrophysiological Concordance Groups (Timed Up and Go)
Zeitfenster: At Day 0 (single assessment; no follow-up)
|
To investigate differences in functional mobility according to clinical-electrophysiological concordance, mobility will be assessed using the Timed Up and Go (TUG) test, measuring the time required to rise from a chair, walk three meters, turn, return to the chair and sit down. Completion time will be recorded in seconds and compared across the three predefined concordance groups. Inability to complete the test safely will be recorded as a non-feasible assessment rather than assigned an arbitrary completion time. |
At Day 0 (single assessment; no follow-up)
|
|
Pain Intensity Across Clinical-Electrophysiological Concordance Groups
Zeitfenster: At Day 0 (single assessment; no follow-up).
|
To investigate whether pain intensity differs according to clinical-electrophysiological concordance, average pain intensity over the preceding seven days will be assessed using an 11-point numerical rating scale, ranging from 0 (no pain) to 10 (worst imaginable pain). Pain scores will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up).
|
|
Patient-Perceived Disease Severity Across Clinical-Electrophysiological Concordance Groups
Zeitfenster: At Day 0 (single assessment; no follow-up)
|
To evaluate differences in patient-perceived disease severity according to clinical-electrophysiological concordance, overall disease severity will be self-rated using a five-point ordinal scale ranging from 1 (very mild) to 5 (very severe). Scores will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Work Absenteeism Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
Zeitfenster: At Day 0 (single assessment; no follow-up)
|
To investigate differences in work absenteeism associated with Charcot-Marie-Tooth disease according to clinical-electrophysiological concordance, absenteeism will be assessed using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) and quantified as the percentage of working time missed due to the disease during the preceding seven days, ranging from 0% to 100%. Comparisons will be performed across the three predefined concordance groups among employed participants for whom the measure is applicable. |
At Day 0 (single assessment; no follow-up)
|
|
Work Presenteeism Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
Zeitfenster: At Day 0 (single assessment; no follow-up).
|
To investigate differences in work-related productivity impairment while present at work according to clinical-electrophysiological concordance, presenteeism will be assessed using the WPAI:SHP questionnaire and expressed as the percentage of impairment while working attributable to Charcot-Marie-Tooth disease during the preceding seven days, ranging from 0% to 100%. Results will be compared across the three predefined concordance groups among participants for whom the measure is applicable. |
At Day 0 (single assessment; no follow-up).
|
|
Overall Work Productivity Impairment Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
Zeitfenster: At Day 0 (single assessment; no follow-up).
|
To assess whether overall work productivity impairment differs according to clinical-electrophysiological concordance, overall impairment will be calculated from the absenteeism and presenteeism components of the WPAI:SHP questionnaire and expressed as a percentage ranging from 0% (no impairment) to 100% (complete impairment) over the preceding seven days. Results will be compared across the three predefined concordance groups among participants for whom the measure is applicable |
At Day 0 (single assessment; no follow-up).
|
|
Daily Activity Impairment Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
Zeitfenster: At Day 0 (single assessment; no follow-up)
|
To assess differences in the impact of Charcot-Marie-Tooth disease on usual daily activities according to clinical-electrophysiological concordance, activity impairment will be quantified using the WPAI:SHP questionnaire and expressed as a percentage ranging from 0% (no impairment) to 100% (complete impairment) over the preceding seven days. Results will be compared across the three predefined concordance groups, irrespective of employment status |
At Day 0 (single assessment; no follow-up)
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Angela Puma, Centre Hospitalier Universitaire de Nice
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Nervensystems
- Neuromuskuläre Erkrankungen
- Genetische Krankheiten, angeboren
- Erkrankungen des peripheren Nervensystems
- Neurodegenerative Krankheiten
- Angeborene Anomalien
- Heredodegenerative Erkrankungen, Nervensystem
- Missbildungen des Nervensystems
- Polyneuropathien
- Hereditäre sensorische und motorische Neuropathie
- Angeborene, erbliche und neonatale Krankheiten und Anomalien
- Charcot-Marie-Tooth-Krankheit
Andere Studien-ID-Nummern
- 26Neuro06
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .